Thomas Jefferson University

Jefferson Digital Commons
Department of Pathology, Anatomy, and Cell
Biology Faculty Papers

Department of Pathology, Anatomy, and Cell
Biology

1-1-2012

Kaempferol nanoparticles achieve strong and selective inhibition
of ovarian cancer cell viability.
Haitao Luo
1 Department of Biology, Natural Science Division, Alderson-Broaddus College, Philippi

Bingbing Jiang
, School of Medicine, West Virginia University

Bingyun Li
, School of Medicine, West Virginia University

Zhaoliang Li
1
Department
Biology, Natural
Science
Division, Alderson-Broaddus College, Philippi
Follow
this andofadditional
works at:
https://jdc.jefferson.edu/pacbfp
Part of Jiang
the Medical Anatomy Commons, Medical Cell Biology Commons, and the Medical Pathology
Bing-Hua

Thomas Jefferson University
Commons

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Luo, Haitao; Jiang, Bingbing; Li, Bingyun; Li, Zhaoliang; Jiang, Bing-Hua; and Chen, Yi Charlie,
"Kaempferol nanoparticles achieve strong and selective inhibition of ovarian cancer cell
viability." (2012). Department of Pathology, Anatomy, and Cell Biology Faculty Papers. Paper
107.
https://jdc.jefferson.edu/pacbfp/107
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Pathology, Anatomy, and Cell Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Haitao Luo, Bingbing Jiang, Bingyun Li, Zhaoliang Li, Bing-Hua Jiang, and Yi Charlie Chen

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/pacbfp/107

International Journal of Nanomedicine

Dovepress
open access to scientific and medical research

O ri g inal R esearch

Open Access Full Text Article

Kaempferol nanoparticles achieve strong
and selective inhibition of ovarian cancer
cell viability
This article was published in the following Dove Press journal:
International Journal of Nanomedicine
23 July 2012
Number of times this article has been viewed

Haitao Luo 1
Bingbing Jiang 2
Bingyun Li 2–4
Zhaoliang Li 1
Bing-Hua Jiang 5
Yi Charlie Chen 1
Department of Biology, Natural
Science Division, Alderson-Broaddus
College, Philippi, 2Department of
Orthopaedics, School of Medicine,
West Virginia University, 3WVNano
Initiative, 4Mary Babb Randolph
Cancer Center, Morgantown, WV,
USA; 5Department of Pathology,
Anatomy and Cell Biology, Thomas
Jefferson University, Philadelphia,
PA, USA
1

Correspondence: Bingyun Li
Biomaterials, Bioengineering, and
Nanotechnology Laboratory, Mary
Babb Randolph Cancer Center and
Department of Orthopaedics, School
of Medicine, West Virginia University,
Morgantown, WV 26506-9196, USA
Tel +1 304 293 1075
Fax +1 304 293 7070
Email bli@hsc.wvu.edu
Yi Charlie Chen
Department of Biology, Natural Science
Division Alderson-Broaddus College,
Philippi, WV 26416, USA
Tel +1 304 457 6277
Fax +1 304 457 6239
Email chenyc@ab.edu

submit your manuscript | www.dovepress.com

Dovepress
http://dx.doi.org/10.2147/IJN.S33670

Abstract: Ovarian cancer is one of the leading causes of cancer death for women throughout
the Western world. Kaempferol, a natural flavonoid, has shown promise in the chemoprevention
of ovarian cancer. A common concern about using dietary supplements for chemoprevention is
their bioavailability. Nanoparticles have shown promise in increasing the bioavailability of some
chemicals. Here we developed five different types of nanoparticles incorporating kaempferol
and tested their efficacy in the inhibition of viability of cancerous and normal ovarian cells.
We found that positively charged nanoparticle formulations did not lead to a significant reduction in cancer cell viability, whereas nonionic polymeric nanoparticles resulted in enhanced
reduction of cancer cell viability. Among the nonionic polymeric nanoparticles, poly(ethylene
oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) nanoparticles incorporating kaempferol led to significant reduction in cell viability of both cancerous and normal cells.
Poly(DL-lactic acid-co-glycolic acid) (PLGA) nanoparticles incorporating kaempferol resulted
in enhanced reduction of cancer cell viability together with no significant reduction in cell
viability of normal cells compared with kaempferol alone. Therefore, both PEO-PPO-PEO and
PLGA nanoparticle formulations were effective in reducing cancer cell viability, while PLGA
nanoparticles incorporating kaempferol had selective toxicity against cancer cells and normal
cells. A PLGA nanoparticle formulation could be advantageous in the prevention and treatment
of ovarian cancers. On the other hand, PEO-PPO-PEO nanoparticles incorporating kaempferol
were more effective inhibitors of cancer cells, but they also significantly reduced the viability
of normal cells. PEO-PPO-PEO nanoparticles incorporating kaempferol may be suitable as a
cancer-targeting strategy, which could limit the effects of the nanoparticles on normal cells while
retaining their potency against cancer cells. We have identified two nanoparticle formulations
incorporating kaempferol that may lead to breakthroughs in cancer treatment. Both PEO-PPOPEO and PLGA nanoparticle formulations had superior effects compared with kaempferol alone
in reducing cancer cell viability.
Keywords: nanochemoprevention, kaempferol, ovarian cancer, nanoparticles, viability, natural
compound

Introduction
Natural compounds with antioxidant properties that function to protect the human
body against development of cancer1,2 are present in a variety of fruit and vegetables.3
Natural dietary compounds have been reported to reduce the risk of development of
diabetes,4 cardiovascular disease,5 prostate cancer,6 colorectal cancer,7 and ovarian
cancer.8 Kaempferol (3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one)
is a relatively common nontoxic, natural dietary compound which has been reported
to reduce the risk of ovarian cancer.9 Kaempferol was found to inhibit estrogen
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receptor alpha expression in breast cancer cells10 and to
induce apoptosis in glioblastoma cells11 and lung cancer
cells12 by activation of MEK-MAPK. Studies have shown
that kaempferol also has anti-inflammatory effects via inhibition of interleukin-413 and cyclo-oxygenase 2 expression
by suppressing Src kinase14 and downregulating the NFκB
pathway.15 Kaempferol is also effective in inhibiting angiogenesis and inducing apoptosis in ovarian cancer cells.16–19
In human studies, a significant 40% decrease in incidence
of ovarian cancer was found for individuals with the highest
quintile of kaempferol intake as compared with those in the
lowest quintile.20 Despite promising preclinical results, the
utility of such compounds for chemoprevention in humans
has met with only limited success, largely due to inefficient
systemic delivery and limited bioavailability of promising
agents. Therefore, to achieve the maximum response to
a chemopreventive agent, novel strategies are required to
enhance the bioavailability of potentially useful agents and
to reduce toxicity.
Nanotechnology is an emerging interdisciplinary field
that encompasses biology, engineering, chemistry, and
medicine.21 Using nanotechnology for the development
of efficient anticancer drug delivery systems is a recent
advance in medical science.22–24 The ability of nanoparticles
to incorporate entities renders them ideal carriers for various
anticancer drugs.25,26 Because most anticancer drugs have
poor solubility in water and low bioavailability, the use of
nanocarriers enables cancer medications with low solubility in water to be prepared as solid or liquid formulations.
Nanoparticles comprised of biodegradable polymers have
been studied for delivery of drugs.27,28 Significant advantages
of using biodegradable polymers are their safety and the
ability to control the time and rate of polymer degradation as
well as timely release of the drug. Nanoparticles comprised of
biodegradable polymers such as poly(lactic acid), poly(DLlactic acid-co-glycolic acid) (PLGA), poly(caprolactone),
palmitic acid, and chitosan have been utilized for the delivery
of anticancer drugs.27,28 In recent years, nanotechnology has
been implemented and assessed in different areas of cancer
therapeutics and management.29 Siddiqui et al reported
that nanoencapsulated epigallocatechin-3-gallate retains
its biological effectiveness, with over a 10-fold dose reduction advantage compared with nonencapsulated epigallocatechin-3-gallate when inhibiting cell growth, and proapoptotic
and angiogenic effects.30
Ovarian cancer is one of the leading causes of cancer
death in women throughout the Western world.31 There has
been limited progress in the prevention, early diagnosis,
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and treatment of ovarian cancer to date,32,33 leaving this
malignancy with an unchanged death rate over decades.31
Chemoprevention of ovarian cancer using natural products
has received more attention recently, and our earlier studies
have indicated that kaempferol, a dietary flavonoid, is effective in inhibiting angiogenesis and inducing apoptosis in
ovarian cancer cells.16–19 However, effective concentrations
are often above 20–40 µM, which are not always physiologically attainable. In this study, five nanoparticle formulations
of kaempferol were developed and their efficacy in inhibiting the viability of malignant and normal ovarian cells was
determined.

Materials and methods
Chemicals
Kaempferol (soluble, 50 mg/mL in dimethyl sulfoxide), polyethylenimine (PEI, molecular weight 800 Da), PLGA (lactide
to glycolide ratio 50:50, molecular weight 30–60 kDa), glycol
chitosan, poly(amidoamine) (PAMAM) dendrimer (molecular weight 516), and polyvinyl alcohol (molecular weight
31–50 kDa), tetrahydrofuran, ethanol, acetone, dimethyl
sulfoxide, and Dulbecco’s phosphate-buffered saline solution were purchased from Sigma-Aldrich (St Louis, MO).
Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene
oxide) (PEO-PPO-PEO, Pluronic P123 surfactant) was
obtained from BASF Corporation (Mount Olive, NJ). The
chemical structures of kaempferol, PLGA, PEO-PPO-PEO,
glycol chitosan or chitosan, PLGA-PEI, and PAMAM dendrimer are shown in Figure 1. The PLGA-PEI polymer was
synthesized using an aminolysis approach. In brief, PLGA
was dissolved in tetrahydrofuran and PEI was dissolved in
ethanol. The two solutions were then mixed at a PLGA to PEI
mass ratio of 10:1 and stirred at 50°C for 30 minutes to form
PLGA-PEI. The polymer solution was then dialyzed using a
2 kDa dialysis membrane for 2 days and lyophilized.

Synthesis and characterization
of nanoparticles incorporating kaempferol
The PEO-PPO-PEO, PLGA, PLGA-PEI, chitosan, and
PAMAM nanoparticles were studied, and found to be biodegradable and to have good biocompatibility with normal cells
and tissues. These five nanoparticles incorporated with and
without kaempferol were synthesized using a nanoprecipitation method.34 In brief, kaempferol was dissolved in dimethyl
sulfoxide at a concentration of 0.2 M. PLGA, PAMAM,
PEO-PPO-PEO, and PLGA-PEI were dissolved in acetone at
a concentration of 20 g/L. Chitosan was dissolved in deionized water at a concentration of 200 g/L and further mixed
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Figure 1 Chemical structures of kaempferol, PLGA, PEO-PPO-PEO, glycol chitosan, PLGA-PEI, and PAMAM dendrimer.
Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PLGA, poly(DL-lactic acid-co-glycolic acid); PEI, polyethyleneimine;
PAMAM, poly(amidoamine).

with acetone to 20 g/L before synthesis of the nanoparticles.
To synthesize the nanoparticles incorporating kaempferol,
250 µL of kaempferol solution was mixed with 1 mL of
polymer solution. Five mL of Dulbecco’s phosphate-buffered
saline solution was added dropwise and gently stirred with
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a magnetic bar for 30 minutes. The solution was kept under
ventilation for 6 hours and then gradually vacuumed until no
vapor was observed. The resulting solution was concentrated
at 2.5 mM under a speed vacuum concentrator (Thermo Fisher
Scientific, Waltham, MA) or lyophilized as a powder; for
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lyophilized samples, Dulbecco’s phosphate-buffered saline
solution was replaced with deionized water. To prepare
the PLGA nanoparticles, polyvinyl alcohol was used as
a surfactant and added in Dulbecco’s phosphate-buffered
saline solution at a concentration of 0.5 wt%. Nanoparticles
incorporating kaempferol were diluted and their size and
surface potential were characterized using a 2000 Zetasizer
(Malvern Instruments, Worcestershire, UK).

Cell culture
IOSE397 cells are normal ovarian surface epithelial cells
immortalized with SV40 T/t, and were gifted for this research
by Dr Nelly Auersperg, University of British Columbia,
Canada. A2780/CP70 and OVCAR-3 ovarian cancer cell
lines were from Dr Bing-Hua Jiang at Thomas Jefferson
University, Philadelphia, PA. All cells were maintained in
RPMI 1640 medium (Sigma-Aldrich) supplemented with
10% fetal bovine serum (Life Technologies, Carlsbad, CA)
at 37°C with 5% CO2.

Cell viability assay
Kaempferol alone, nanoparticles without kaempferol, kaempferol mixed with but not incorporated into nanoparticles,
and nanoparticles incorporating kaempferol were tested for
their effects on the viability of malignant and/or normal
ovarian cells. To test the effects of kaempferol alone and
nanoparticles incorporating kaempferol, the cells were
seeded in microplates at 8000 cells per well, incubated at
37°C overnight, and treated with kaempferol or nanoparticles
for 24 hours. Cell viability was analyzed using a CellTiter
96 Aqueous one solution cell proliferation assay kit from
Promega Corporation (Madison, WI). Optical density (OD)
values were recorded at 490 nm.

Statistical analysis

The results were expressed as the mean ± standard error of the
mean. During the screening process, optical density values
were compared by t-test. For indepth analysis of selected
nanoparticles, independent experiments were normalized
and combined for statistical analysis. Statistical significance
was set at P , 0.05.

Results and discussion
The synthesized PEO-PPO-PEO, PLGA, PLGA-PEI, chitosan, and PAMAM nanoparticles were approximately 200 nm
in size (Table 1). The PEO-PPO-PEO and PLGA nanoparticles had almost no surface charge, while chitosan, PLGAPEI, and PAMAM nanoparticles had a positive surface
charge, with PAMAM having the highest charge (Table 1).
3954
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Table 1 Particle size and zeta potential of nanoparticles
incorporating kaempferol (data are an average of three samples)
Nanoparticle

Particle size (nm)

Surface potential (mV)

PLGA
PEO-PPO-PEO
Chitosan
PLGA-PEI
PAMAM

210 ± 40
160 ± 30
230 ± 70
220 ± 50
250 ± 70

+0.1 ± 3.4
+1.4 ± 4.2
+11.7 ± 5.9
+34.2 ± 7.9
+37.2 ± 8.3

Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly
(ethylene oxide); PLGA, poly(DL-lactic acid-co-glycolic acid); PEI, polyethyleneimine;
PAMAM, poly(amidoamine).

We screened the five different types of kaempferol
nanoparticles for their ability to inhibit viability of A2780/
CP70 cancer cells. As shown in Figure 2A–F, kaempferol in
25 µM phosphate-buffered saline solution did not achieve
any significant reduction in cell viability compared with
unexposed controls. Neither nanoparticles plus kaempferol
nor nanoparticles alone resulted in any significant change
in A2780/CP70 cell viability compared with kaempferol in
phosphate-buffered saline solution or the control. In contrast,
PEO-PPO-PEO nanoparticles incorporating kaempferol
achieved significant inhibition of A2780/CP70 cells and
resulted in significant reduction in cell viability compared
with kaempferol in phosphate-buffered saline solution (Figure 2A). PLGA nanoparticles incorporating kaempferol also
showed marginally significant inhibitory effects compared
with kaempferol in phosphate-buffered saline solution
(P = 0.07, Figure 2B). The other three types of nanoparticle
(ie, PLGA-PEI, chitosan, and PAMAM) did not achieve a
significant reduction in A2780/CP70 cell viability compared
with kaempferol in phosphate-buffered saline solution or the
control, and no significant differences in ability to reduce
cell viability were observed between these three nanoparticle
types (Figure 2F).
These data suggest that nanoparticle chemistry plays an
important role in the treatment of cancer if nanoparticles are
used. Appropriate nanoparticle formulation or chemistry (ie,
PEO-PPO-PEO) can lead to significant reduction of cancer
cell viability (see Figure 1A). Positively charged nanoparticles did not result in reduction of A2780/CP70 cell viability,
while nonionic polymeric (eg, PEO-PPO-PEO) nanoparticles
led to significant reduction in A2780/CP70 cell viability.
We also examined these chemicals in another ovarian cancer cell line (ie, OVCAR-3). Consistent with the
screening results for A2780/CP70 cells, PEO-PPO-PEO
and PLGA nanoparticles incorporating kaempferol resulted
in significantly lower OVCAR-3 cell viability compared
with kaempferol in phosphate-buffered saline solution and
the control (Figure 3). PLGA-PEI, chitosan, and PAMAM
International Journal of Nanomedicine 2012:7
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Figure 2 Effects of nanoparticles incorporating kaempferol on A2780/CP70 ovarian cancer cells.
Notes: Ovarian cancer cells were seeded in a microplate, incubated overnight, and treated with 25 µM kaempferol for 24 hours. Cell viability was analyzed using an
MTS-based method. *P , 0.05 as compared with kaempferol in phosphate-buffered saline solution and control.
Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; NP, nanoparticle; OD, optical density; PEO-PPO-PEO,
poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PAMAM, poly(amidoamine); PBS, phosphate-buffered saline solution; PLGA, poly(DL-lactic acid-co-glycolic acid).

nanoparticles resulted in higher cell viability compared
with kaempferol in phosphate-buffered saline solution
(Figure 3). Comparing Figures 2F and 3, PEO-PPO-PEO
and PLGA nanoparticles incorporating kaempferol led to
lower viability of both A2780/CP70 and OVCAR-3 cancer
cells than did kaempferol in phosphate-buffered saline
International Journal of Nanomedicine 2012:7

solution, but the degree of reduction was significantly different. Moreover, PEO-PPO-PEO and PLGA nanoparticles
incorporating kaempferol showed greater activity against
OVCAR-3 cells than A270/CP70 cells. This is consistent
with the effect of kaempferol alone because kaempferol
25 µM in phosphate-buffered saline solution significantly
submit your manuscript | www.dovepress.com
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Figure 3 Effects of nanoparticles incorporating kaempferol on OVCAR-3 ovarian cancer cells.
Notes: OVCAR-3 cells were seeded in a microplate, incubated overnight, and treated with 25 µM kaempferol for 24 hours. Cell viability was analyzed using an MTS-based
method. **P , 0.01, *P , 0.05 versus control. #P , 0.01 versus kaempferol in phosphate-buffered saline solution.
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reduced the viability of OVCAR-3 cells (Figure 3) but not
A2780/CP70 cells (Figure 2F). These findings suggest that
the treatment outcome depends on the type of cancer cell,
and PEO-PPO-PEO and PLGA nanoparticles incorporating
kaempferol could have potential application in different
forms of ovarian cancer (even when kaempferol alone does
not have a significant impact).
The effects of PEO-PPO-PEO and PLGA nanoparticles
incorporating kaempferol were further compared with
kaempferol in phosphate-buffered saline solution for their
inhibitory effects on cancerous and normal ovarian cells
at two different concentrations (10 µM and 25 µM). As
shown in Figure 4, at 10 µM, PLGA nanoparticles incorporating kaempferol significantly reduced the viability of
OVCAR-3 cells but had no significant influence on the
viability of IOSE397 cells. This result was also found at
the 25 µM concentration. However, PEO-PPO-PEO nanoparticles incorporating kaempferol significantly reduced the
viability of both OVCAR-3 and IOSE397 cells compared
with kaempferol in phosphate-buffered saline solution at
concentrations of 10 µM and 25 µM. Overall, the higher
the concentration (from 10 µM to 25 µM), the greater the
reduction in OVCAR-3 cell viability. Moreover, it seemed
that, at the same concentration, PEO-PPO-PEO nanoparticles incorporating kaempferol were more effective in
reducing OVCAR-3 cell viability compared with PLGA
nanoparticles incorporating kaempferol, with a significant
reduction seen at 10 µM (Figure 4A). PEO-PPO-PEO
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Figure 4 Effects of PEO-PPO-PEO and PLGA nanoparticles incorporating
kaempferol on OVCAR-3 ovarian cancer cells and immortalized IOSE397 epithelial
ovarian cells at (A) 10 µM and (B) 25 µM. Ovarian cells were seeded in microplates,
incubated overnight, and treated with kaempferol or its nanoparticles for 24 hours.
Notes: Viability of cells was measured using an MTS-based method. Data represent the
mean ± standard error of the mean from a minimum of three independent experiments.
*P , 0.05, **P , 0.01 versus kaempferol in phosphate-buffered saline solution. #P , 0.01
versus PLGA nanoparticles incorporating kaempferol in treating the same cell type.
Abbreviations: MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H-tetrazolium; PBS, phosphate-buffered saline solution; NP, nanoparticle;
PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide); PLGA,
poly(DL-lactic acid-co-glycolic acid).
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Table 2 Summary of the effects of PEO-PPO-PEO and PLGA
nanoparticles incorporating kaempferol on cancerous and normal
ovarian cells studied
Cell
Cancer cell
A2780/CP70
OVCAR-3
Normal cell
IOSE397

Kaempferol-PLGA
NP

KaempferolPEO-PPO-PEO NP

§
¶

¶
¶*

**

¶^

Notes: ¶Significant reduction in viability compared with kaempferol in PBS; §notable
reduction (P = 0.07) in viability compared with kaempferol in PBS; **no significant
difference in viability compared with kaempferol in PBS; *significant reduction in
viability at a low concentration (ie, 10 μM) but not at a high concentration (ie, 25 μM)
compared with kaempferol-PLGA nanoparticles; ^significant reduction in viability
versus kaempferol-PLGA nanoparticles.
Abbreviations: PEO-PPO-PEO, poly(ethylene oxide)-poly(propylene oxide)poly(ethylene oxide); PLGA, poly(DL-lactic acid-co-glycolic acid); NP, nanoparticle;
PBS, phosphate-buffered saline solution.

nanoparticles incorporating kaempferol also resulted in
significant reduction of IOSE397 cell viability compared
with PLGA nanoparticles incorporating kaempferol
(Figure 4). These results suggest that incorporation of
kaempferol into PEO-PPO-PEO and PLGA nanoparticles
enhanced the effectiveness of kaempferol in reducing the
viability of cancer cells, and PEO-PPO-PEO nanoparticles
incorporating kaempferol were more effective than PLGA
nanoparticles incorporating kaempferol. PLGA nanoparticles incorporating kaempferol could discriminate between
cancerous and normal cells, whereby the viability of cancer
cells but not the normal cells was significantly affected by
PLGA nanoparticles incorporating kaempferol compared
with kaempferol alone.
It is worth mentioning that developing effective strategies for targeting anticancer drugs or nanoparticles has
also attracted attention.35–39 Sunoqrot et al recently reported
a hybrid nanoparticle platform that may allow targeting
kinetics to be effectively controlled through hybridization
of targeted dendrimers using polymeric nanoparticles.39
In their study, folate-targeted PAMAM dendrimers were
incorporated into poly(ethylene glycol)-b-poly(D,Llactide) nanoparticles, and their combined passive and
active targeting enabled precise control over the targeting
kinetics of dendrimers to folate-overexpressing cells.39
Similarly, folate-targeted kaempferol complexes could
be incorporated into our PEO-PPO-PEO or PLGA nanoparticles to achieve high targeting efficacy against folateoverexpressing cancerous cells while limiting potential
effects on normal cells.

International Journal of Nanomedicine 2012:7

Conclusion
Five nanoparticle formulations incorporating kaempferol
were investigated for their potential in the treatment of ovarian
cancer, and their efficacy was tested in vitro. Table 2 summarizes the effects of PEO-PPO-PEO and PLGA nanoparticles
incorporating kaempferol on cancerous and normal ovarian
cells. In A2780/CP70 ovarian cancer cells, we found that
nanoparticles incorporating kaempferol with positive charges
(ie, PLGA-PEI, glycol chitosan, and PAMAM dendrimer)
did not significantly reduce cell viability. PEO-PPO-PEO
nanoparticles incorporating kaempferol significantly reduced
cell viability compared with kaempferol alone, and PLGA
nanoparticles incorporating kaempferol also showed notably
enhanced reduction of the viability of A2780/CP70 cells.
PEO-PPO-PEO and PLGA nanoparticles incorporating kaempferol also significantly reduced the viability of OVCAR-3
cancer cells, compared with kaempferol alone. These two
kaempferol nanoparticles were further compared with
kaempferol alone in immortalized IOSE397 ovarian cells
and OVCAR-3 ovarian cancer cells. We found that PEOPPO-PEO nanoparticles incorporating kaempferol not only
significantly reduced the viability of OVCAR-3 cancer cells
but also that of normal IOSE397 cells compared with kaempferol alone. Interestingly, PLGA nanoparticles incorporating
kaempferol significantly reduced the viability of OVCAR-3
cancer cells but not normal IOSE397 cells compared with
kaempferol alone. Therefore, the PLGA nanoparticle formulation could be a promising candidate for cancer treatment
due to its improved ability to reduce cancer cell viability
along with no significant reduction in the viability of normal
ovarian cells. PEO-PPO-PEO nanoparticles incorporating
kaempferol were more effective in inhibiting the viability of
cancer cells compared with PLGA nanoparticles incorporating kaempferol. If appropriately targeted, PEO-PPO-PEO
nanoparticles incorporating kaempferol could be more effective in treating cancer. The mechanisms related to the effects
of PEO-PPO-PEO and PLGA nanoparticles incorporating
kaempferol on cancerous and normal ovarian cells are still
unclear, so further investigation of these nanoparticles for better nanochemoprevention of cancer is warranted.
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